TAGline Fall 2013
The Domestic Issue: We're at a stalemate. This issue of TAGline underscores TAG’s commitment to ending AIDS in the United States and realizing the goals of the National HIV/AIDS Strategy.
Letter Urging UNITAID to Prioritize HIV/HCV Coinfection
TAG and 134 other organizations sent this letter to underscore the need for a swift response from UNITAID to hepatitis C virus (HCV) coinfection; delays will cost lives and impede scale-up when more effective and tolerable therapies are available.
Adenovirus Vaccine Vectors and HIV Acquisition Risk: The View from the Summit
On September 19th, 2013, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored a daylong mini-summit to discuss the safety of adenovirus vaccine vectors in populations at risk for HIV infection.
Community Advocates Letter to U.S. Government Partners of the Conference on Retroviruses and Opportunistic Infections
We are writing to express serious concern and dismay regarding the shutting down of the website for the Conference on Retroviruses and Opportunistic Infections (CROI).
The Cost of Flat Funding for Biomedical Research
August 12, 2013 “The Costs of Flat Funding for Biomedical Research,” an issue brief prepared by the Foundation for AIDS Research (amfAR) in collaboration with TAG, examines the declining purchasing value of public funding for health research at the National…
Broad Coalition of HIV/AIDS Advocates and Advocacy Organizations Urge Patient Groups to Support AllTrials Initiative
A broad coalition of HIV/AIDS advocates and advocacy organizations urge patient groups to support the AllTrials Initiative.
HIV i-Base/Treatment Action Group 2013 Pipeline Report calls on leaders to get the best HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, and vaccines to the most people as quickly as possible
HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
2013 Pipeline Report
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development: Written by Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, and Tracy Swan
U.S. Centers for Disease Control and Prevention (CDC) Sponsored HIV Preexposure Prophylaxis (PrEP) Trial among Thai Injection Drug Users Marred by Lack of Response to Community Concerns
On June 12, results from an efficacy trial of tenofovir as pre-exposure prophylaxis (PrEP) against HIV infection in individuals with a self-reported history of injection drug use were published in the Lancet. The trial was sponsored by the U.S. Centers for Disease Control and Prevention (CDC) and took place in Bangkok, Thailand (named the Bangkok Tenofovir Study). The publication was accompanied by a flurry of press releases and drew considerable news coverage due to the documentation of a statistically significant reduction in risk of HIV acquisition of 48.9%.
Tenefovir Alafenamide Fumarate (TAF) Sign-On Letter to Gilead
TAG and Other Orgs Issued this letter to Gilead about TAF.